Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Histological improvement (dichotomous) · active EoE pediatric patients

It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.19 [0.37, 3.77]
1 study · 39 participants
Very low

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

Histological improvement (dichotomous) · active EoE pediatric patients

It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 2.5 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.56 [0.23, 1.37]
1 study · 40 participants
Very low

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Histological improvement (dichotomous) · active EoE pediatric patients

It is very uncertain whether mepolizumab 2.5 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 2.14 [0.79, 5.79]
1 study · 39 participants
Very low